The Best Information on Mesothelioma

When you're dealing with a serious illness, like Mesothelioma, it’s natural to want to search for every legitimate possible treatment or therapy to fight the progression of the disease.

There is research going on all over the world to improve mesothelioma treatment. According to the U.S. National Institutes of Health, one recent trial recruiting participants is going on at Memorial Sloan-Kettering Cancer Center in New York City. In this particular clinical trial, patients must have a histologically confirmed diagnosis of epithelioid, sarcomatoid, or mixed-type malignant pleural mesothelioma that is not amenable to surgery.

As described on the website www.clinicaltrials.gov , a service of NIH, the purpose is to determine the rate of clinical benefit (i.e. rate of complete or partial response plus stable disease) at 16 weeks for patients with malignant mesothelioma treated with everolimus as second or third line therapy. [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

The clinical trial description also includes the following secondary measure, among others:
• To determine the response rate, time to progression and overall survival for patients with mesothelioma treated with everolimus. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
If you or someone you know is dealing with the horrific effects of asbestos exposure, find out what your rights are to hold the manufacturers and users of asbestos responsible.
Contact us at 1-800-443-6353, or learn more about our mesothelioma practice at www.hendlerlaw.com .